Antibiotic treatment regimens for bone infection after debridement: a study of 902 cases

CURRENT STATUS: ACCEPTED

Xiaohua Wang
Southwest Hospital

Li Fang
Southwest Hospital

Shulin Wang
Southwest Hospital

Yueqi Chen
Southwest Hospital

Huan Ma
Southwest Hospital

Hongwen Zhao
Southwest Hospital

Zhao Xie
xiezhao54981@163.com Corresponding Author

DOI:
10.21203/rs.2.18846/v4

SUBJECT AREAS
Orthopedics

KEYWORDS
Bone infection, short-term antibiotic, liver damage, renal damage
Abstract

**Background:** Our aim was to investigate the clinical efficacy and complications of antibiotic treatment regimens for patients with bone infection.

**Methods:** We retrospectively analysed patients with bone infection admitted to our hospital between March 2013 and October 2018. After surgical debridement was performed, the patients were divided into three groups: IV group (intravenous antibiotics for two weeks); oral group (intravenous antibiotics for two weeks followed by oral antibiotics for four weeks); and rifampicin group (intravenous antibiotics for two weeks followed by oral antibiotics plus rifampicin for four weeks). The infection control rate and complications were compared among the three groups.

**Results:** A total of 902 patients were enrolled. The infection sites included 509 tibias, 228 femurs, 32 humeri, 23 radii and ulnae, 40 calcanei, and 47 miscellaneous sites, as well as 23 multiple-site infections. After at least six months of follow-up, 148 (16.4%) patients had an infection recurrence. The recurrence rate of the IV group was 17.9%, which was not significantly higher than the recurrence rates of the oral group (10.1%) and rifampicin group (10.5%), \(P=0.051\). The incidence of abnormal alanine aminotransferase (ALT) levels in the IV group was 15.1%, which was lower than that in the oral group (18.0%) and rifampicin group (27.4%), \(P=0.026\). The rates of proteinuria in the three groups were 3.2%, 4.5%, and 9.3%, respectively, \(P=0.020\).

**Conclusions:** After debridement of bone infection, short-term antibiotic treatment regimens might offer similar rates of infection eradication while avoiding the risk of renal and hepatic damage associated with prolonged antibiotic use.

**The Level of Clinical Relevance:** Stage III.

**Background**

Bone infection is a common complication after bone fracture. Although modern medical advancements have brought the treatment of bone infections to a new height, it is still a difficult disease for orthopaedic doctors to treat. The commonly used treatments include conservative debridement, continuous flushing, antibiotic carrier filling, and others. To achieve the desired results, clinicians frequently use parenteral antibiotic therapy at a high dose for prolonged periods [1].
However, intravenous therapy carries substantial risks, and it is inconvenient for patients [2]. In particular, long-term intravenous antibiotic therapy may cause complications such as catheter-related bloodstream infections and thrombosis [3]. Currently, the mainstay treatment method is debridement followed by systemic antibiotic therapy, which commonly includes intravenous infusion for two weeks followed by oral antibiotics for 4-6 weeks [4, 5]. However, there is no evidence that antibiotic therapy for 4-6 weeks leads to improved outcomes compared with shorter regimens [1]. Moreover, the long-term application of antibiotics may lead to adverse liver and kidney reactions [6]. The route and duration of antibiotics after debridement is important for infection eradication. Scholars are trying to reduce the use of antibiotics, but there is currently no accepted plan. In this study, we explored the use of a 2-week IV antibiotics regimen in the treatment of bone infection, and the overall efficacy was adequate.

Patients And Methods
After receiving approval from our institutional review board, we retrospectively analysed patients with bone infection admitted to our hospital between March 2013 and October 2018. The diagnosis of bone infection was made based on the presence of local bone pain and swelling during examination, imaging procedures, microbiological and histopathological examinations, and laboratory studies (such as biopsy, which is the gold standard, or deep tissue culture) [7]. The inclusion criteria were as follows: bone infection; treatment with debridement and subsequent filling with antibiotic cement; and use of postoperative systemic antibiotics. The exclusion criteria were as follows: diabetic foot infection; no surgical treatment; autoimmune disease and generalized vascular insufficiency; incomplete follow-up data; preoperative liver or kidney dysfunction; or bone graft performed within six months after debridement. The study flow chart is shown in Fig. 1.

Treatment methods
In all patients, debridement was performed, and antibiotic cement was implanted. After the cement was removed (following eradication of the infection), bone grafts were performed to repair the bone defects. In this study, only the infection control process was considered; the process of repairing the bone defect was not evaluated. During the operation, sequestrum and necrotic tissue were removed,
and bacteria were identified by a drug susceptibility test. After debridement, bone defects were filled with antibiotic polymethyl methacrylate (PMMA) cement (Heraeus, Germany). The appropriate fixation method (plate internal fixation, plate external fixation, no fixation) was chosen considering the Cierny-Mader classification, and negative pressure drainage was allowed for 10 to 12 days. The patients were divided into three groups according to whether oral antibiotics were taken after surgery: an IV group (intravenous antibiotics for two weeks); an oral group (intravenous antibiotics for two weeks followed by oral antibiotics for four weeks); and a rifampicin group (intravenous antibiotics for two weeks followed by oral antibiotics plus rifampicin for four weeks). There were no significant differences in any of the following general data: fixation method used; Cierny-Mader classification; or bacterial infection. The bacterial infection and the types and doses of antibiotics used are shown in Table 1.

Postoperative management and follow-up

All patients were examined by laboratory tests and urine protein tests on the 1st, 7th, and 14th days after surgery. Subsequently, the same examinations were repeated weekly for the oral group and rifampicin group, and urine protein was repeatedly examined until the 6th week. The infection control and recurrence criteria are as follows [6]: an apparent cure was defined as the absence of signs or symptoms of osteomyelitis for at least six months after the cessation of antimicrobial therapy. A relapse was defined as an infection occurring at the same site from which it was apparently eliminated, requiring specific treatment with antibiotics or surgery. ALT and aspartic transaminase (AST) values greater than 40 U/L and creatinine (Cr) values greater than 104 µmol/L were defined as abnormal.

Statistics

One-way analysis of variance (or the rank sum test, where relevant) was used to compare measurement data (recurrent time). Pearson's chi-square test was used to compare enumeration data (ALT, AST, and Cr levels, proteinuria, infection control rate). A P value below 0.05 was considered significant.

Results
A total of 902 patients were enrolled in this study. There were 717 males and 185 females with an average age of 40.25 (4-76) years. The mean duration of infection before admittance to the hospital was 70.7 months (14 days to 720 months). The infection sites included 509 tibias, 228 femurs, 32 humeri, 23 radii and ulnae, 40 calcanei, and 47 miscellaneous sites, as well as 23 multiple-site infections. There were 666 cases of post-traumatic infection and 236 cases of haematogenous osteomyelitis. Bacteria were isolated from 640 (71%) patients. Of these patients, 307 (48.0%) were infected with *Staphylococcus aureus* (including 81 with MRSA), 56 (8.8%) with *Pseudomonas aeruginosa*, 41 (6.4%) with *Escherichia coli*, 33 (5.2%) with *Enterobacter cloaca*, 39 (6.0%) with *Staphylococcus epidermidis*, 25 (3.9%) with *Klebsiella pneumoniae*, 64 (10%) with other bacteria, 75 (11.7%) with more than one bacteria, and the remaining 262 cases were negative.

There were 148 (16.4%) recurrent infections within the six-month follow-up period, with an average recurrence time of 63.0±4.8 (4-176) days. The recurrence rate of the IV group was 17.9% (130/727), which was not significantly higher than that of the oral group (10.1%, 9/89) and the rifampicin group (10.5%, 9/86); P=0.051. The recurrence times of the three groups were 62.37±6.93, 58.56±13.44, and 76.33±17.48 days, respectively; P=0.851. There were 727 patients in the IV group, of which 130 patients relapsed. The highest recurrence rate was observed among patients with *P. aeruginosa* infections, who had a recurrence rate of 40.4% (19/47), while the recurrence rate of patients with no isolated bacteria was 8.1% (19/236); P<0.01.

The rate of abnormal ALT levels in the IV group was 15.1%, which was lower than that of the oral group (18.0%) and rifampicin group (27.4%); P=0.026. The rates of proteinuria in the three groups were 3.2%, 4.5%, and 9.3%, respectively; P=0.020. There were no significant differences in the rates of abnormal AST (P=0.798) and Cr (P=0.620) levels among the three groups. The results are shown in Table 2.

**Discussions**

Treatment of bone infection is a difficult procedure. At present, the overall treatment strategy includes conservative treatment, palliative debridement, en bloc resection, and amputation, but there is a lack of uniform treatment standards. Surgery is the usual method chosen by clinicians, but not all
cases require surgical debridement [1], and many infections can be effectively treated with oral therapy [8-10]. Hamed [11] reported that intravenous antibiotics (six weeks) and oral suppression therapy were administered for cases of PJI infection, with reliable clinical efficacy. Research has shown that drug therapy alone has an average success rate of 71.1%, while surgical treatment alone has an average success rate of 88.9% [12]. Systemic intravenous antibiotics after debridement can achieve a rapid reduction in the bacterial load at the site of infection [13]. Therefore, clinicians are more inclined to use surgical treatment combined with antibiotic treatment to stop the infection.

According to previous studies, the optimal treatment of acute haematogenous osteomyelitis involves intravenous antibiotics for several weeks and then oral antibiotics until the symptoms and signs are alleviated [14, 15]. However, for chronic bone infection, debridement is often the first choice. Although research has shown that oral and parenteral therapies achieve similar success rates [1], clinicians are accustomed to considering the use of intravenous antibiotics [16, 17], followed by oral antibiotics for several weeks, during hospitalizations. It has been reported that the use of intravenous antibiotics for less than one week has no significant effect on prognosis [18-20]. However, only limited data comparing intravenous antibiotics and oral antibiotics or concerning proper treatment durations are available. We applied debridement plus systemic antibiotic treatment. Most patients (80.6%) were treated with intravenous antibiotics for only two weeks, although long-term antibiotic use has achieved good results in previous reports. Our results showed that the recurrence rate of the IV group was not significantly different from that of the other two groups, and the overall infection control rate was 83.6%. The infection control rate is comparable to that of previous reports, providing support for the treatment of these patients with short-term systemic antibiotic regimens following debridement.

Multiple and refractory bacterial infections are common in bone infections, especially chronic infections, so combined antibiotic treatments are commonly applied in the clinic. The most common oral combination drug is rifampicin, which has a bactericidal effect on multiple gram-positive and gram-negative bacteria [17]. Rifampicin can achieve high intracellular levels and is capable of penetrating bacterial biofilms [21, 22]. However, it is not advisable to only apply rifampicin for anti-infection treatment because resistance can quickly develop [5]. Thus, rifampicin should be started
after the bacterial load is reduced by surgery and when the wound is dry [23, 24]. In this study, 307 (48.0%) patients were infected with *Staphylococcus aureus* and 56 (8.8%) with *Pseudomonas aeruginosa*, accounting for more than 50% of the isolated bacteria, so levofloxacin was applied more often in our clinic. Levofloxacin alone was unable to eradicate methicillin-susceptible *S. aureus* [25, 26]. The classic antibiotic combination for bone infections caused by *Staphylococcus aureus* and *P. aeruginosa* is levofloxacin plus rifampicin.

It is difficult to assess how long it will take for an infection to clear following the treatment of bone infection. Urania Rappo [27] evaluated the efficacy of infection after six weeks of treatment. Daver NG [6] indicated that the infection is apparently cured if it does not recur within six months. We evaluated infection control at six months after the operation. Although this timing may miss some cases of recurrence, our statistical analysis shows that recurrence occurs within two months in most cases.

Although rifampicin is rarely used alone in the treatment of bone infections, when this drug used in combination with other antibiotics, rifampicin can increase the treatment outcomes of other antibiotics. Rifampicin diffuses very well within bone tissue and bacterial biofilms [28] and is a valuable treatment option. However, rifampicin often elicits a hepatotoxic response and leads to gastroenteropathy. Our results indicated that the rate of abnormal ALT levels in the rifampicin group was significantly higher than that in the other groups, suggesting that postoperative combinations including rifampicin may lead to liver damage. In addition, Sahoko [29] reported that rifampicin can cause acute renal damage. Our results show that the overall complication rate was acceptable in the three groups. The recurrence rate of the IV group was not significantly different from that of the other two groups. Moreover, the oral group and rifampicin group had higher ALT levels and proteinuria rates, and the abnormal levels were probably caused by the additional oral therapies. Although the proteinuria rate in the rifampicin group was the highest, the rate of abnormal creatinine levels was not significantly different, suggesting that the additional rifampicin therapies may cause early or mild renal damage.

There are many strengths in this article, including the large sample size and its use of standard
techniques. However, there are several drawbacks. First, although our results showed that there was no significant difference in the general data, including the type of bacterial infection and fixation method, the heterogeneity within the cohort may have affected the results. Second, the abnormal ALT and proteinuria levels suggested possible liver and renal damage, but the extent of the damage was not determined. Third, recurrence is common in bone infection, and the long-term recurrence rate for patients (after the six-month follow-up) is unknown.

Conclusions
After debridement of bone infection, short-term antibiotic treatment regimens might offer similar rates of infection eradication while avoiding the risk of renal and hepatic damage associated with prolonged antibiotic use.

Declarations

Ethics approval and consent to participate
Ethics approval was obtained from the Ethics Committee of the First Affiliated Hospital of Army Medical University, PLA. All the participants provided written informed consent.

Consent for publication
All presentations provided consent for publication.

Availability of data
We are unable to share the raw data because ethical approval was not obtained for data sharing. In addition, all data are presented in the Tables.

Competing interests
We declare that there are no conflicts of interest with any institution.

Funding
This work was supported by the General Program of the National Natural Foundation of China (81672160), and the Key Research and Development Program of China (2016YFC1102005) supported the design, data collection, and manuscript writing of this study. There was no funding from any commercial sources for this study.

Authors’ contributions
XW and LF contributed to collecting the data, writing the paper, and analysing the data and performed the surgeries. SW contributed to the collecting the data. YC contributed to the writing the paper and revising the article. HM and LF contributed to providing medication guidance and assessing liver and kidney damage. ZX and HZ contributed to overall planning and analysing the data and performed the surgeries. All authors have read and approved the final version of this manuscript. **Acknowledgements** None.

**Abbreviations**

ALT, Alanine aminotransferase; AST, Aspartic transaminase; Cr, Creatinine; MSSA, Methicillin-susceptible Staphylococcus aureus; MSSE, Methicillin-susceptible epidermidis.

**References**

1. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clinical infectious diseases: an official publication of the. Infectious Diseases Society of America. 2012; 54(3):393-407.

2. Li HK, Scarborough M, Zambellas R, Cooper C, Rombach I, Walker AS, Lipsky BA, Briggs A, Seaton A, Atkins B. Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial. Trials. 2015; 16:583.

3. Valbousquet Schneider L, Jr., Duron S, Arnaud FX, Bousquet A, Kervella Y, Bouzad C, Baccialone J, A’Teriitehau C, Potet J. Evaluation of PICC complications in orthopedic inpatients with bone infection for long-term intravenous antibiotics therapy. The journal of vascular access. 2015; 16(4):299-308.

4. Rod-Fleury T, Dunkel N, Assal M, Rohner P, Tahintzi P, Bernard L, Hoffmeyer P, Lew D, Uckay I. Duration of post-surgical antibiotic therapy for adult chronic osteomyelitis: a single-centre experience. International orthopaedics. 2011; 35(11):1725-1731.

5. Trampuz A, Zimmerli W. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury. 2006; 37 Suppl 2:S59-66.
6. Daver NG, Shelburne SA, Atmar RL, Giordano TP, Stager CE, Reitman CA, White AC, Jr. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. The Journal of infection. 2007; 54(6):539-544.

7. Mouzopoulos G, Kanakaris NK, Kontakis G, Obakponovwe O, Townsend R, Giannoudis PV. Management of bone infections in adults: the surgeon's and microbiologist's perspectives. Injury. 2011; 42(Suppl. 5):S18–23.

8. Oosterheert JJ, Bonten MJ, Schneider MM, Buskens E, Lammers JW, Hustinx WM, Kramer MH, Prins JM, Slee PH, Kaasjager K et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. Bmj. 2006; 333(7580):1193.

9. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clinical infectious diseases. 2002; 34(11):1481-1490.

10. Montini G, Toffolo A, Zucchetta P, Dall'Amico R, Gobber D, Calderan A, Maschio F, Pavanello L, Molinari PP, Scorrano D et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. Bmj. 2007; 335(7616):386.

11. Vahedi H, Aali-Rezaie A, Shahi A, Conway JD. Irrigation, Debridement, and Implant Retention for Recurrence of Periprosthetic Joint Infection Following Two-Stage Revision Total Knee Arthroplasty: A Matched Cohort Study. The Journal of arthroplasty. 2019; 34(8):1772-1775.

12. Maffulli N, Papalia R, Zampogna B, Torre G, Albo E, Denaro V. The management of osteomyelitis in the adult. The surgeon. 2016; 14(6):345-360.

13. Metsemakers WJ, Kuehl R, Moriarty TF, Richards RG, Verhofstad MHJ, Borens O, Kates S, Morgenstern M. Infection after fracture fixation: Current surgical and
microbiological concepts. Injury. 2018; 49(3):511-522.

14. Peltola H, Pääkkönen M. Acute Osteomyelitis in Children. New England Journal of Medicine. 2014; 370(4):352-360.

15. Vaughan PA, Newman NM, Rosman MA. Acute hematogenous osteomyelitis in children. Journal of pediatric orthopedics. 1987; 7(6):652-655.

16. Lew DP, Waldvogel FA. Osteomyelitis. The Lancet. 2004; 364(9431):369-379.

17. Mader JT, Shirliff ME, Bergquist SC, Calhoun J. Antimicrobial treatment of chronic osteomyelitis. Clinical orthopaedics and related research. 1999; (360):47-65.

18. Peltola H, Paakkonen M, Kallio P, Kallio MJ. Osteomyelitis-Septic Arthritis Study G: Short- versus long-term antimicrobial treatment for acute hematogenous osteomyelitis of childhood: prospective, randomized trial on 131 culture-positive cases. The Pediatric infectious disease journa. 2010; l 29(12):1123-1128.

19. Peltola H, Paakkonen M, Kallio P, Kallio MJ, Group O-SS. Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood--a prospective quasi-randomized controlled trial. Clinical microbiology and infection. 2012; 18(6):582-589.

20. Dartnell J, Ramachandran M, Katchburian M. Haematogenous acute and subacute paediatric osteomyelitis: a systematic review of the literature. The Journal of bone and joint surgery British volume. 2012; 94(5):584-595.

21. Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Archives of internal medicine. 2008; 168(8):805-819.

22. Blaser J, Vergeres P, Widmer AF, Zimmerli W. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrobial agents and chemotherapy. 1995; 39(5):1134-1139.
23. Sendi P, Zimmerli W. Antimicrobial treatment concepts for orthopaedic device-related infection. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012; 18(12):1176-1184.

24. Achermann Y, Eigenmann K, Ledergerber B, Derksen L, Rafeiner P, Clauss M, Nuesch R, Zellweger C, Vogt M, Zimmerli W. Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control study. Infection. 2013; 41(2):431-437.

25. John AK, Baldoni D, Haschke M, Rentsch K, Schaerli P, Zimmerli W, Trampuz A. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrobial agents and chemotherapy. 2009; 53(7):2719-2724.

26. Trampuz A, Murphy CK, Rothstein DM, Widmer AF, Landmann R, Zimmerli W. Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. Antimicrobial agents and chemotherapy. 2007; 51(7):2540-2545.

27. Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL, Suen A, Mas Casullo V, Melnick D, Miceli R et al. Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety. Open forum infectious diseases. 2019; 6(1):ogy331.

28. Coiffier G, Albert J-D, Arvieux C, Guggenbuhl P. Optimizing combination rifampin therapy for staphylococcal osteoarticular infections. Joint Bone Spine. 2013; 80(1):11-17.

29. Chiba S, Tsuchiya K, Sakashita H, Ito E, Inase N. Rifampicin-induced acute kidney injury during the initial treatment for pulmonary tuberculosis: a case report and literature review. Internal medicine. 2013; 52(21):2457-2460.
**Tables**

Table 1. The bacteria and the antibiotics we used

| Bacteria                                      | Intravenous antibiotics | Adults                                               | Pediatrics                                           |
|------------------------------------------------|-------------------------|------------------------------------------------------|------------------------------------------------------|
| MSSA/MSSE                                     | Cefazolin: 2g q8h. Cefuroxime: 1.5g q8h. Ceftriaxone: 2g q12h. Levofoxacin: 600mg qd, Moxifoxacin: 400mg qd | Cefazolin: 2g q8h. Cefuroxime: 1.5g q8h. Ceftriaxone: 2g q12h. Levofoxacin: 600mg qd, Moxifoxacin: 400mg qd |
| MRSA/MRSE                                     | Vancomycin: 15–20mg/Kg q8–12h. Linezolid: 600mg q12h | Vancomycin: 40mg/(kg.d) 2 to 4 times/d. Linezolid: 10mg/kg q8h |
| *P. aeruginosa/E. coli/E. cloaca/K. pneumoniae* | Ceftazidime: 2g q8h/Cefepime: 2g q12h/PiperacillinTazobactam: 4.5g q8h / Levofloxacin: 500mg qd/Amikacin: 15mg/Kg qd (usually used in combination) | Ceftazidime: 30-100mg/(kg.d) Cefepime: 40mg/Kg q12h. PiperacillinTazobactam: 112.5 |
| Others                                        | According to drug sensitivity | According to drug sensitivity |
| Negative                                      | Ceftazidime / Cefepime / Fluoroquinolone | Ceftazidime 20-80mg/(kg.d) q4h |

MSSA/MSSE: Methicillin-susceptible *Staphylococcus aureus/ epidermidis*. The dosage is suitable for patients with no serious liver and renal dysfunction.
Table 2: Comparisons of general information, clinical efficacy of the three groups

| Events                              | IV group  | Oral group | Rifampicin group | P Value |
|-------------------------------------|-----------|------------|------------------|---------|
| Number                              | 727       | 89         | 86               | -       |
| Sex ratio (male/female)             | 3.9 (578/149) | 4.6 (73/16) | 3.3 (66/20)      | 0.68    |
| Average age (years)                 | 37.11±1.62| 40.30±3.22 | 38.91±2.54       | 0.13    |
| Average duration of infection (months) | 70.3±6.5 | 68.1±11.8  | 75.9±8.1         | 0.25    |
| Type of infection                   | 541/186   | 67/22      | 58/28            | 0.36    |
| (posttraumatic/hematologic)         |           |            |                  |         |
| Recurrence rate of infection        | 17.9%130/727 | 10.1%9/89  | 10.5%9/86        | 0.05    |
| Recurrence time (days)              | 62.37±6.93| 58.56±13.44| 76.33±17.48      | 0.85    |
| Abnormal rate of ALT                | 15.1%110/727 | 18.0%16/89 | 27.9%24/86       | 0.02    |
| Abnormal rate of AST                | 16.4%119/727 | 14.6%13/89 | 13.9%12/86       | 0.79    |
| Abnormal rate of Cr                 | 1.1%8/727  | 1.1%1/89   | 2.3%2/86         | 0.62    |
| Positive rates of proteinuria       | 3.2%23/727 | 4.5%4/89   | 9.3%8/86         | 0.02    |

ALT: Alanine aminotransferase; AST: Aspartic transaminase; Cr: Creatinine

Figures
Fig. 1 The study flow chart

Figure 1

The study flow chart.